207 related articles for article (PubMed ID: 10439681)
1. [Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
Castelló Viguer MT; Echánove Errazti I; Ridocci Soriano F; Esteban Esteban E; Atienza Fernández F; Cuesta Estellés G
Rev Esp Cardiol; 1999 Jul; 52(7):533-5. PubMed ID: 10439681
[TBL] [Abstract][Full Text] [Related]
2. Pentavalent antimonial-induced torsade de pointes.
Ortega-Carnicer J; Alcázar R; De la Torre M; Benezet J
J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610
[TBL] [Abstract][Full Text] [Related]
3. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
Segura I; García-Bolao I
Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
[TBL] [Abstract][Full Text] [Related]
4. [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV].
Trinchieri V; Ferone U; Monacelli M; Isceri L; Proietti F; Sorice F
Riv Eur Sci Med Farmacol; 1996; 18(2):49-51. PubMed ID: 9213843
[TBL] [Abstract][Full Text] [Related]
5. [Torsade de pointes secondary to treatment with pentavalent antimonial drugs].
Temprano Vázquez S; García Salazar MA; Jiménez Martín MJ; López Martínez J
Med Clin (Barc); 1998 May; 110(18):717. PubMed ID: 9656226
[No Abstract] [Full Text] [Related]
6. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
[No Abstract] [Full Text] [Related]
7. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
Castro C; Sampaio RN; Marsden PD
Trans R Soc Trop Med Hyg; 1990; 84(3):362. PubMed ID: 2260169
[No Abstract] [Full Text] [Related]
8. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
Hantson P; Léonard ED; Crutzen-Fayt MC; Léonard A; Vandercam B; Delaere B; Mahieu P
Pharmacotherapy; 1996; 16(5):869-71. PubMed ID: 8888081
[TBL] [Abstract][Full Text] [Related]
9. Severe leucopenia during treatment of visceral leishmaniasis.
Hiçsönmez G; Jama H; Ozsoylu S
Trans R Soc Trop Med Hyg; 1988; 82(3):417. PubMed ID: 3232176
[No Abstract] [Full Text] [Related]
10. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
Saldanha AC; Romero GA; Merchan-Hamann E; Magalhães AV; Macedo Vde O
Rev Soc Bras Med Trop; 1999; 32(4):383-7. PubMed ID: 10495667
[TBL] [Abstract][Full Text] [Related]
11. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
12. Meglumine antimoniate-induced pancreatitis.
Torrús D; Massa B; Boix V; Portilla J; Pérez-Mateo M
Am J Gastroenterol; 1996 Apr; 91(4):820-1. PubMed ID: 8677970
[No Abstract] [Full Text] [Related]
13. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
Kuyucu N; Kara C; Bakirtaç A; Teziç T
Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
[TBL] [Abstract][Full Text] [Related]
14. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala.
Navin TR; Arana BA; Arana FE; de Mérida AM; Castillo AL; Pozuelos JL
Am J Trop Med Hyg; 1990 Jan; 42(1):43-50. PubMed ID: 2405727
[TBL] [Abstract][Full Text] [Related]
15. [Symptomatic hypokalemia caused by meglumine antimoniate].
Bouvresse S; Matichard E; Mahé E; Marinho E; Soria A; Devillière M; Descamps V; Crickx B
Ann Dermatol Venereol; 2007 Apr; 134(4 Pt 1):387-8. PubMed ID: 17483764
[No Abstract] [Full Text] [Related]
16. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
[TBL] [Abstract][Full Text] [Related]
17. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)].
Barthet M; Brunet P; Bernard JC; Dussol B; Rodor F; Jouglard J; Berland Y; Sahel J
Gastroenterol Clin Biol; 1994; 18(1):90-2. PubMed ID: 8187998
[No Abstract] [Full Text] [Related]
18. [Meglumine antimoniate].
Silva JB
Rev Soc Bras Med Trop; 2001; 34(1):103-5. PubMed ID: 11340506
[No Abstract] [Full Text] [Related]
19. Antimony containing drug and ECG abnormalities in children with visceral leishmaniasis.
Zanoni LZ; Brustoloni YM; Melnikov P; Cônsolo CE
Biol Trace Elem Res; 2009 Dec; 132(1-3):35-40. PubMed ID: 19424667
[TBL] [Abstract][Full Text] [Related]
20. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
